NCT02296567 - Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Age Related Macular Degeneration

Interventions

DRUG

Ranibizumab

Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.

DRUG

Bevacizumab

Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.

DRUG

Aflibercept

Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.

DRUG

Ranibizumab

Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.

DRUG

Bevacizumab

Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care

DRUG

Aflibercept

Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care

DRUG

Ranibizumab

Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care

DRUG

Bevacizumab

Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care

DRUG

Aflibercept

Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care

OTHER

Control Group

Control group Subjects will no previous anti-VEGF treatment

Trial Locations (1)

RECRUITING

East Florida Eye Institute, Stuart